Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
ch-toulon.frTotal trials
75
Active
22
Phase 3
3
Total enrollment
22,179
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Repotrectinib | — | — | — | — | — | 1 |
Next readouts
- 2031-09
Top conditions
- Pulmonary Embolism3
- Chronic Obstructive Pulmonary Disease (COPD)3
- Respiratory Distress Syndrome2
- Covid-192
- COVID-192
- Deep Vein Thrombosis2
- Drug Use2
- Sars-CoV21
Frequently asked questions about Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
- How many clinical trials does Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer have on ClinicalTrials.gov?
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer is listed as the lead sponsor on 75 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer's trials are in Phase 3?
- 3 of Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer focus on?
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer's most-studied conditions on ClinicalTrials.gov are Pulmonary Embolism, Chronic Obstructive Pulmonary Disease (COPD), Respiratory Distress Syndrome, Covid-19, COVID-19.
- When are Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer's next clinical trial readouts?
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer has 1 upcoming primary-completion readout tracked here; the soonest is “Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC”, expected around 2031-09.